DOCSLIB.ORG

A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report THE NATIONAL ACADEMIES PRESS This PDF is available at http://www.nap.edu/24731 SHARE A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report DETAILS 296 pages | 6 x 9 | PAPERBACK ISBN 978-0-309-45729-3 | DOI: 10.17226/24731 CONTRIBUTORS GET THIS BOOK Gillian J. Buckley and Brian L. Strom, Editors; Committee on a National Strategy for the Elimination of Hepatitis B and C; Board on Population Health and Public Health Practice; Health and Medicine FIND RELATED TITLES Division; National Academies of Sciences, Engineering, and Medicine Visit the National Academies Press at NAP.edu and login or register to get: – Access to free PDF downloads of thousands of scientific reports – 10% off the price of print titles – Email or social media notifications of new titles related to your interests – Special offers and discounts Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. (Request Permission) Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Copyright © National Academy of Sciences. All rights reserved. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report Gillian J. Buckley and Brian L. Strom, Editors Committee on a National Strategy for the Elimination of Hepatitis B and C Board on Population Health and Public Health Practice Health and Medicine Division A Report of Copyright © National Academy of Sciences. All rights reserved. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report THE NATIONAL ACADEMIES PRESS 500 Fifth Street, NW Washington, DC 20001 This activity was supported by the American Association for the Study of Liver Diseases, the Infectious Diseases Society of America, the National Viral Hepatitis Roundtable, and the U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (Contract No. 200-2011-38807, Task Order #44). Any opinions, findings, conclusions, or recommendations expressed in this publica- tion do not necessarily reflect the views of any organization or agency that provided support for the project. International Standard Book Number-13: 978-0-309-45729-3 International Standard Book Number-10: 0-309-45729-7 Digital Object Identifier: https://doi.org/10.17226/24731 Library of Congress Control Number: 2017942500 Additional copies of this publication are available for sale from the National Acad- emies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624- 6242 or (202) 334-3313; http://www.nap.edu. Copyright 2017 by the National Academy of Sciences. All rights reserved. Printed in the United States of America Suggested citation: National Academies of Sciences, Engineering, and Medi- cine. 2017. A national strategy for the elimination of hepatitis B and C: Phase two report. Washington, DC: The National Academies Press. doi: https://doi. org/10.17226/24731. Copyright © National Academy of Sciences. All rights reserved. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report The National Academy of Sciences was established in 1863 by an Act of Congress, signed by President Lincoln, as a private, nongovernmental institution to advise the nation on issues related to science and technol- ogy. Members are elected by their peers for outstanding contributions to research. Dr. Marcia McNutt is president. The National Academy of Engineering was established in 1964 under the charter of the National Academy of Sciences to bring the practices of engineering to advising the nation. Members are elected by their peers for extraordinary contributions to engineering. Dr. C. D. Mote, Jr., is president. The National Academy of Medicine (formerly the Institute of Medicine) was established in 1970 under the charter of the National Academy of Sciences to advise the nation on medical and health issues. Members are elected by their peers for distinguished contributions to medicine and health. Dr. Victor J. Dzau is president. The three Academies work together as the National Academies of Sci- ences, Engineering, and Medicine to provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions. The National Academies also encourage education and research, recognize outstand- ing contributions to knowledge, and increase public understanding in matters of science, engineering, and medicine. Learn more about the National Academies of Sciences, Engineering, and Medicine at www.national-academies.org. Copyright © National Academy of Sciences. All rights reserved. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report Reports document the evidence-based consensus of an authoring committee of experts. Reports typically include findings, conclusions, and recommendations based on information gathered by the committee and committee deliberations. Reports are peer reviewed and are approved by the National Academies of Sciences, Engineering, and Medicine. Proceedings chronicle the presentations and discussions at a workshop, sym- posium, or other convening event. The statements and opinions contained in proceedings are those of the participants and have not been endorsed by other participants, the planning committee, or the National Academies of Sciences, Engineering, and Medicine. For information about other products and activities of the National Academies, please visit nationalacademies.org/whatwedo. Copyright © National Academy of Sciences. All rights reserved. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report COMMITTEE ON A NATIONAL STRATEGY FOR THE ELIMINATION OF HEPATITIS B AND C BRIAN L. STROM (Chair), Chancellor, Biomedical and Health Sciences, Rutgers University, The State University of New Jersey JON KIM ANDRUS, Adjoint Professor and Senior Investigator, Division of Vaccines and Immunization, Center for Global Health, University of Colorado Denver ANDREW ARONSOHN, Associate Professor of Medicine, University of Chicago DANIEL CHURCH, Senior Epidemiologist, Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health SEYMOUR S. COHEN, American Cancer Society Research Professor, retired ALISON EVANS, Associate Professor, Dornsife School of Public Health, Drexel University PAUL KUEHNERT, Assistant Vice President, Program, Robert Wood Johnson Foundation VINCENT LO RE III, Assistant Professor of Medicine (Infectious Diseases) and Epidemiology, University of Pennsylvania KATHLEEN MAURER, Director, Health and Addiction Services, Connecticut Department of Correction RANDALL MAYER, Chief, Bureau of HIV, STD, and Hepatitis, Division of Behavioral Health, Iowa Department of Public Health SHRUTI MEHTA, Professor of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University STUART C. RAY, Professor of Medicine, Center for Viral Hepatitis Research, Division of Infectious Diseases, Johns Hopkins University ARTHUR REINGOLD, Edward Penhoet Distinguished Professor of Global Health and Infectious Diseases, School of Public Health, University of California, Berkeley SAMUEL SO, Lui Hac Minh Professor, School of Medicine, Stanford University NEERAJ SOOD, Professor and Vice Dean for Research, Sol Price School of Public Policy and Schaeffer Center for Health Policy & Economics, University of Southern California GRACE WANG, Family Physician, International Community Health Services LUCY WILSON, Chief, Center for Surveillance, Infection Prevention, and Outbreak Response, Maryland Department of Health and Mental Hygiene v Copyright © National Academy of Sciences. All rights reserved. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report Study Staff GILLIAN J. BUCKLEY, Study Director AIMEE MEAD, Research Associate SOPHIE YANG, Research Assistant MARJORIE PICHON, Senior Program Assistant DORIS ROMERO, Financial Associate ROSE MARIE MARTINEZ, Director, Board on Population Health and Public Health Practice James C. Puffer, M.D./American Board of Family Medicine (ABFM) Fellow GERARDO MORENO, University of California, Los Angeles Consultants HOMIE RAZAVI, Center for Disease Analysis MEHLIKA TOY, Stanford University School of Medicine TIMOTHY WESTMORELAND, Georgetown University Law Center vi Copyright © National Academy of Sciences. All rights reserved. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report Reviewers his report has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise. The purpose of Tthis independent review is to provide candid and critical comments that will assist the institution in making its published report as sound as possible and to ensure that the report meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the deliberative process. We wish to thank the following individuals for their review of this report: HARVEY ALTER, National Institutes of Health Clinical Center SANJAY BASU, Stanford Prevention Research Center JOHN BIRGE, The University of Chicago Booth School of Business JULES DIENSTAG, Harvard Medical School SHELLY F. GREENFIELD, McLean Hospital RUTH KATZ, The Aspen Institute ANNA LOK, University of Michigan Medical School DAVID MENDEZ, University of Michigan School of Public Health WALTER O. ORENSTEIN, Emory University School of Medicine ROBIN
Load more

Recommended publications
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Pharmacology
    Step I Pharmacology 'WSMU~ is a ~aint program 0~the lfederatlan° a"• State Meaieal Boaras a~the I!Jntitea States • lne, and the Natianal Baara a1 Medieal Examiners. USMLE·Step 1 Pharmacology Lecture Notes 2006-2007 Edition KAPLA~. I meulca • USMLE is a joint program of the Federation of State Medical Boards of the United States, Inc. and the National Board of Medical Examiners. ©2006 Kaplan, Inc. All rights reserved. No part of this book may be reproduced in any form, by photostat, microfilm, xerography or any other means, or incorporated into any information retrieval system, electronic or mechanical, without the written permission of Kaplan, Inc. Not for resale. Author Lionel P. Rayman, Pharm.D., Ph.D. Department of Pathology Forensic Toxicology Laboratory University of Miami School of Medicine Miami, FL Contributing Authors Director of Medical Curriculum Sonia Reichert, M.D. Craig Davis, Ph.D. Associate Professor Editorial Director University of South Carolina School of Medicine Department of Pharmacology, Physiology, and Neuroscience Kathlyn McGreevy Columbia, SC Production Manager Maris Victor Nora, Pharm.D., Ph.D. Michael Wolff Associate Professor Rush Medical College Production Editor Chicago.Tl. William Ng Anthony Trevor, Ph.D. Cover Design Professor Emeritus Joanna Myllo Department of Cellular and Molecular Pharmacology University of California Cover Art San Francisco, CA Christine Schaar Steven R. Harris, Ph.D. Associate Dean for Basic Sciences Associate Professor of Pharmacology Pikeville College School of Osteopathic Medicine
    [Show full text]
  • Key Enzymes in Cancer: Mechanism of Action and Inhibition with Anticancer Agents
    University of Texas Rio Grande Valley ScholarWorks @ UTRGV Chemistry Faculty Publications and Presentations College of Sciences 2018 Key Enzymes in Cancer: Mechanism of Action and Inhibition With Anticancer Agents Debasish Bandyopadhyay The University of Texas Rio Grande Valley, [email protected] Gabriel Lopez The University of Texas Rio Grande Valley Stephanie Cantu The University of Texas Rio Grande Valley Samantha Balboa The University of Texas Rio Grande Valley Annabel Garcia The University of Texas Rio Grande Valley See next page for additional authors Follow this and additional works at: https://scholarworks.utrgv.edu/chem_fac Part of the Chemistry Commons, and the Life Sciences Commons Recommended Citation Debasish Bandyopadhyay, Gabriel Lopez, Stephanie Cantu, Samantha Balboa, Annabel Garcia, Christina Silva, Diandra Valdes. In Chemistry Research and Applications (Vol. 2): Organic and Medicinal Chemistry, Chapter 9; Key Enzymes in Cancer: Mechanism of Action and Inhibition with Anticancer Agents. 2018, Nova Science Publishers, Inc., Hauppauge, New York, USA (ISBN: 978-1-53614-855-8). This Book is brought to you for free and open access by the College of Sciences at ScholarWorks @ UTRGV. It has been accepted for inclusion in Chemistry Faculty Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact [email protected], [email protected]. Authors Debasish Bandyopadhyay, Gabriel Lopez, Stephanie Cantu, Samantha Balboa, Annabel Garcia, Christina Silva, and Diandra Valdes This book is available at ScholarWorks @ UTRGV: https://scholarworks.utrgv.edu/chem_fac/131 In: Organic and Medicinal Chemistry, Volume 2 ISBN: 978-1-53614-855-8 Editor: Bimal Krishna Banik © 2019 Nova Science Publishers, Inc.
    [Show full text]
  • UMBC Alumnae Racing to Develop Coronavirus Vaccine
    Newsletter SPRING 2020 To our UMBC/Meyerhoff families: We hope you and your families are all doing well during this strange and stressful time of Covid- 19. Although the world has changed quickly with so many things shut down and many of us sheltering at home, we hope this newsletter will represent a ray of sunshine during a dark and difficult time. Please enjoy this positive representation of our student and alumni community. MPA Board UMBC Alumnae Racing to Develop Coronavirus Vaccine Kizzmekia Corbett ’08, M16, biological sciences, says it feels like she’s “living in a constant adrenaline rush.” Maybe that’s because she and her team at the Vaccine Research Center at the National Insti- tute of Allergy and Infectious Diseases have been working around the clock for weeks. They’re racing to develop a vaccine for the coronavirus faster than it can race across the globe. “To be living in this moment where I have the opportunity to work on something that has imminent global importance…it’s just a surre- al moment for me,” Corbett says. Despite it feeling surreal, the advances Corbett and her team are making are very real, and they’re setting records. “We are making better progress than I could have ever hoped for,” she says. After three months of studies in test tubes and in animals, the vaccine her team developed is about to enter a phase I clinical trial, a crucial hur- dle on the way to FDA approval. Read the complete article about Kizzmekia and her team’s efforts to develop a Covid-19 vaccine in the latest UMBC magazine at https:// Kizzmekia Corbett, NIH magazine.umbc.edu/umbc-alumnae-racing-to-develop- coronavirus-vaccine/.
    [Show full text]
  • Activation of Apoptosis Pathways by Different Classes of Anticancer Drugs
    Research Laboratory of Children's Hospital, University of Ulm Chairman: Prof. Dr. Klaus-Michael Debatin Activation of apoptosis pathways by different classes of anticancer drugs Dissertation for the applying for a Doctor Degree of Medicine (Dr. med.) Faculty of Medicine, University of Ulm Presented by Jiahao Liu Born in Hubei, P. R. China 2001 Amtierender Dekan: Prof. Dr. R. Marre 1. Berichterstatter: Prof. Dr. K. M. Debatin 2. Berichterstatter: Prof. Dr. Dr. Dr. A. Grünert Tag der Promotion: 26. 10. 2001 To my family: Chen Longgui & Liu Chang 1 Contents Contents 1 Abbreviations 4 1. Introduction 1.1. Apoptosis: definitions and mechanisms 6 1.1.1. Cell biology of apoptosis 6 1.1.2. Execution of programmed cell death by caspases 7 1.1.3. Two main pathways of apoptosis 8 1.2. Cytotoxic anticancer drugs and apoptosis 9 1.3. Aims and summary of the project 11 2. Materials and Methods 2.1. Materials 14 2.1.1. Reagents and equipment for cell culture 14 2.1.2. Reagents and equipment for flow cytometric analysis 14 2.1.3. Reagents and equipment for western blot 15 2.1.4. Anticancer drugs 16 2.1.5. Antibodies 17 2.2. Methods 19 2.2.1. Cell culture 19 2.2.2. Cell preservation and reconstitution 19 2.2.3. Cell stimulation 19 2.2.4. Inhibitor studies 20 2.2.5. Flow cytometry 20 2.2.5.1. Analysis of annexin V and PI positive cells 20 2.2.5.2. Quantification of DNA fragmentation 21 ∆Ψ 2.2.5.3.
    [Show full text]
  • [email protected] CDC/ATSDR Attn
    April 14, 2020 VIA EMAIL: [email protected] CDC/ATSDR Attn: FOIA Office, MS-D54 1600 Clifton Road, N.E. Atlanta, GA 30333 Re: Freedom of Information Act Request Dear FOIA Officer: Citizens for Responsibility and Ethics in Washington (“CREW”) makes this request for records pursuant to the Freedom of Information Act (“FOIA”), 5 U.S.C. § 552, and Centers for Disease Control and Prevention (“CDC”) regulations. First, CREW seeks all communications from January 29, 2020 to the present between the CDC and the following individuals referencing or involving the collection, tracking, reporting, or release of 2019 Novel Coronavirus (“novel coronavirus”) information pertaining to race, ethnicity, primary language, gender, disability status or socioeconomic status: (1) President Trump; (2) White House employees, including anyone with an “*.eop.gov” email domain; (3) attorneys or representatives acting on behalf of President Trump; and/or (4) members of the White House Coronavirus Task Force, specifically: Mike Pence, Vice President of the United States; Dr. Deborah Birx, United States Global AIDS Coordinator; Vice Admiral Jerome Adams, U.S. Surgeon General; Alex Azar, U.S. Secretary of Health and Human Services; Stephen Biegun, U.S. Deputy Secretary of State; Robert Blair, Assistant to the President and Senior Advisor to the Chief of Staff; Dr. Ben Carson, U.S. Secretary of Housing and Urban Development; Ken Cuccinelli, Acting U.S. Deputy Secretary of Homeland Security; Dr. Kelvin Droegemeier, Director of the U.S. Office of Science and Technology; Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases; Joe Grogan, Assistant to the President and Director of the Domestic Policy Council; Stephen Hahn, U.S.
    [Show full text]
  • Evaluation of Acid Ceramidase As Response Predictor and Therapeutic Target in Neoadjuvant Chemoradiotherapy for Rectal Cancer
    Evaluation of Acid Ceramidase as Response Predictor and Therapeutic Target in Neoadjuvant Chemoradiotherapy for Rectal Cancer Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor of Medicine by David Lewis Bowden November 2018 Dedication To my family – you are my inspiration and motivation, thank you for all your love and support. x R A E J x i Declaration The work presented in this thesis was carried out in the Institute of Translational Medicine at the University of Liverpool and facilitated by the Madel research fellowship, supported by Health Education North West. The material contained within this thesis has not been, nor is currently being presented wholly, or in part, for any other degree or qualification. I declare that all the work presented in this thesis has been carried out by me except where indicated below: • Histopathological assessment of tumour regression grading and immunohistochemical expression of acid ceramidase was performed by Dr Michael Wall (FRCPath, Countess of Chester Hospital) • Tissue microarray construction and sectioning was performed by Mr Michael Neill (Liverpool Bio-Innovation Hub Biobank) David Bowden ii Acknowledgements I am indebted to everyone who has helped me with this research. Thank you. I would firstly like to thank my supervisors: Mr Dale Vimalachandran, Dr Neil Kitteringham, Dr Jason Parsons and Mr Paul Sutton. Your doors have always been open and your guidance and advice invaluable. Thank you particularly for your patience. One of the more laborious aspects of the work undertaken was in the assessment of histopathological tumour response and immunohistochemical expression of acid ceramidase on the tissue microarrays.
    [Show full text]
  • White House Briefing Call Notes 7.8.2020
    Office of Intergovernmental Affairs State, Local, and Tribal Leaders – Thank you to the State, local, and Tribal leaders who joined for the White House COVID-19 National Briefing Call on Wednesday, July 8. Attendees heard comprehensive updates and insights on continuing support for State, local, and Tribal response, recovery, and reopening efforts from Larry Kudlow (Assistant to the President for Economic Policy), Secretary Robert Wilkie (U.S. Department of Veterans Affairs), Ambassador Deborah Birx (White House Coronavirus Task Force Coordinator), U.S. Surgeon General Gerome Adams, Deputy Surgeon General Erica Schwartz, and Assistant Secretary Frank Brogan (U.S. Department of Education). Below, please find pertinent announcements from across the Federal family and a brief recap of yesterday's call, including information and guidance from the White House Summit on Reopening America’s Schools. We would also like to flag CDC’s online testing resource page where you can find up-to-date testing information. Recent Announcements Paycheck Protection Program (PPP) Extended Through August: On July 4, President Trump signed legislation (S. 4116) reauthorizing the Paycheck Protection Program through August 8, 2020. Enacted in March as part of the CARES Act, the $669 billion program has approved more than 4.8 million loans totaling more than $520 billion and supporting over 51 million jobs to date. The extension of the program through August will make available the remaining $134 billion to small businesses and qualifying entities. Learn more about the PPP here. Department of the Treasury’s OIG released reporting requirements for CRF recipients: On July 2, Department of the Treasury’s Office of Inspector General (OIG) released a memorandum with instructions for recipients of the CARES Act’s Coronavirus Relief Fund (CRF).
    [Show full text]
  • Discovery of a Paenibacillus Isolate for Biocontrol of Black Rot in Brassicas
    Lincoln University Digital Thesis Copyright Statement The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand). This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use: you will use the copy only for the purposes of research or private study you will recognise the author's right to be identified as the author of the thesis and due acknowledgement will be made to the author where appropriate you will obtain the author's permission before publishing any material from the thesis. Discovery of a Paenibacillus isolate for biocontrol of black rot in brassicas A thesis submitted in partial fulfilment of the requirements for the Degree of Doctor of Philosophy at Lincoln University by Hoda Ghazalibiglar Lincoln University 2014 DECLARATION This dissertation/thesis (please circle one) is submitted in partial fulfilment of the requirements for the Lincoln University Degree of ________________________________________ The regulations for the degree are set out in the Lincoln University Calendar and are elaborated in a practice manual known as House Rules for the Study of Doctor of Philosophy or Masters Degrees at Lincoln University. Supervisor’s Declaration I confirm that, to the best of my knowledge: • the research was carried out and the dissertation was prepared under my direct supervision; • except where otherwise approved by the Academic Administration Committee of Lincoln University, the research was conducted in accordance with the degree regulations and house rules; • the dissertation/thesis (please circle one)represents the original research work of the candidate; • the contribution made to the research by me, by other members of the supervisory team, by other members of staff of the University and by others was consistent with normal supervisory practice.
    [Show full text]
  • History of the Department of Microbiology 1868 – 2009
    June 2015 HISTORY OF THE DEPARTMENT OF MICROBIOLOGY 1868 – 2009 University of Illinois at Urbana-Champaign 1 A HISTORY OF THE DEPARTMENT OF MICROBIOLOGY 1868 – 2009 This 141 year history of the Department of Microbiology includes an article (Chapter 1), written and published in 1959 by the Department, which covers the period 1868 to 1959. I joined the Department in 1953, and my recounting of the Department’s history includes personal observations as well as anecdotes told to me by H. O. Halvorson and others. Later I realized what a unique experience it had been to join a first-class department, and I resolved to play a role in maintaining its research stature. Ralph Wolfe 2 Department of Microbiology History of the Headship: 1950 – 1959 Halvor Halvorson 1960 – 1963 Kim Atwood 1963 – 1972 Leon Campbell 1972 – 1982 Ralph DeMoss 1982 – 1987 Samuel Kaplan 1987 – 1990 Jordan Konisky 1990 – 1991 Ralph Wolfe (Acting Head) 1991 – 1997 Charles Miller 1997 – 2002 John Cronan 2003 – 2004 Jeffrey Gardner (Acting Head) 2005 – Present John Cronan 3 Organization of the History of the Department In Chapters 2 to 6 the data are divided into Academic Decades, each containing the following sections: Section I, an overview of the decade; Section II, some events for each year of the decade; Section III, a summary of the research interests, honors received, publications, and invited off-campus lectures or seminars for each faculty member. These data have been obtained from the annual reports of the faculty submitted to the departmental secretary. 4 CHAPTER 1 1868 – 1959 During this time period the name of the Department was Department of Bacteriology (Anecdotes by Ralph Wolfe) A SHORT HISTORY OF THE DEPARTMENT OF BACTERIOLOGY H.
    [Show full text]
  • Sleepy Times
    DEPARTMENT OF ANESTHESIA AND PERIOPERATIVE MEDICINE SLEEPY TIMES VOLUME 15, ISSUE 4 MAY 2020 Message from the Chairman: Surgeon General, Dr. Jerome Adams, This is our Pearl Harbor. -Scott T. Reeves, MD, MBA I had originally written this opening statement shortly after the Surgeon Inside This Issue: General’s visit to MUSC and months prior to the COVID 19 pandemic. Dr. Jerome Adams is frequently seen standing close to the President Message from Chairman 1-2 during his daily news updates. He is probably most remembered now for Department Champions 3-6 his statement, this is our Pearl Harbor. He was a strong advocate of social distancing prior to all the states coming on board. As you read the Patient Thank You 7 materials below, consider how thoughtful his priorities of Health and Research Corner 8 National Security and Community Health and Economic Prosperity are in light of the recent COVID 19 pandemic. Heart Walk 9 Dr. Jerome Adams is the 20th Surgeon General of the United States. He recently visited Faculty Council 10-11 MUSC and had several initiatives that made an impact personally on me. To start off, it Physician of the Month 11 is incredible that Dr. Adams is an anesthesiologist. Prior to his tenure as surgeon general he was the Health Commissioner of Indiana. As physicians and healthcare advocates, it Covid 19 Serological 12 is imperative that we have not only good intentions but a clear strategy on how to get our Testing message heard and policy implemented. Dr. Adams’ strategy is demonstrating the link Grand Rounds 13 between a community’s and hence persons health and the economic prosperity and I Hung the Moon 14 national security from a community, city, state and country.
    [Show full text]
  • Uniformed Services University Board of Regents
    Uniformed Services University of the Health Sciences “Learning to Care for Those in Harm’s Way” Board of Regents Quarterly Meeting November 5, 2019 BOARD OF REGENTS UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES 208th MEETING November 5, 2019 | 8:00 a.m. Alvarez Board of Regents Room (D-3001) | Bethesda, MD MEETING AGENDA OPEN MEETING 8:00 a.m.: Meeting Call to Order Designated Federal Officer Ms. Sarah Marshall 8:00 - 8:05 a.m.: Opening Comments Chair, USU Board of Regent Dr. Jonathan Woodson 8:05 - 8:10 a.m.: Matters of General Consent Declaration of Board Actions Dr. Woodson 8:10 - 8:20 a.m.: Board Actions Degree Conferrals, Hébert School of Medicine (SOM) Dean, SOM Dr. Arthur Kellermann Degree Conferrals, Inouye Graduate School of Nursing (GSN) Dean, GSN Dr. Carol Romano Degree Conferrals, College of Allied Health Sciences (CAHS) Dean, CAHS Dr. Mitchell Seal Faculty Appointments and Promotions, SOM Dean, SOM Dr. Kellermann Faculty Appointments and Promotions, PDC Executive Dean, PDC Dr. Schneid Faculty Awards, SOM Dean, SOM Dr. Kellermann 8:20 - 8:45 a.m.: Office of the President, Uniformed Services University of the Health Sciences (USU) Report President, USU Dr. Richard Thomas 8:45 - 9:25 a.m.: Member Reports Academics Summary Board Member Dr. Michael Johns Dr. Johns will provide the Board with a summary of reports from the University Registrar; the Office of Accreditation and Organizational Assessment; and the Faculty Senate. Finance and Administration Summary Board Member Dr. Leo Rouse Dr. Rouse will provide the Board with a summary of reports from the Office of the Vice President for Finance and Administration; the Office of the Vice President for Information and Education Technology; the Office of General Counsel; and the Henry M.
    [Show full text]